Kazuki Nozawa, Medical oncologist, shared a post on X:
“pCR after neoadjuvant chemotherapy has long been considered a strong prognostic marker. But adding ultra-sensitive ctDNA changes the picture.
In the PREDICT-DNA trial (NeXT Personal, Personalis, Inc.), ctDNA-negative patients among non-pCR cases showed outcomes comparable to pCR.
Small sample size-but a highly impactful finding.”
Title: The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
Authors: Natasha B. Hunter, Heather A. Parsons, Leslie Cope, Jenna V. Canzoniero, Fabio C.P. Navarro, Sherif El-Refai, Jesus D. Anampa, Joseph A. Sparano, Mothaffar Rimawi, Anna Maria Storniolo, Candace Mainor, Rita Nanda, Angela DeMichele, Gaorav P. Gupta, Erica J. Stringer-Reasor, Filipa Lynce, Erin F. Cobain, Shannon Puhalla, Rachel Jankowitz, Brent Rexer, Ingrid Mayer, E. Shelley Hwang, Kimberly Blackwell, Walid El Ayass, Young Lee, Carol Tweed, Mary Wilkinson, Angela Pennisi, Bonnie Sun, Pamela Wright, Julie R. Gralow, Richard Chen, Sean M. Boyle, Vered Stearns, Antonio C. Wolff, Ben Ho Park
Read the Full Article.
Preclinical Models of Breast Cancer Metastasis: Strengths, Limitations, and Clinical Relevance
